It can even be said that there are no mergers and acquisitions and no giants.

The reason is that from the perspective of product characteristics, the medical device industry has fragmented and discrete manufacturing attributes. Not only are there large differences between various subdivisions, but also product technology changes rapidly. New technologies often have an impact on old technologies.

Subversive.

From a market perspective, the ceiling in the medical device segment is obvious.

If it cannot further expand its market share, fierce external competition will quickly reduce its market share, and only through mergers and acquisitions can it break through the ceiling of a single product.

Large medical device companies account for 40% of their independent R&D and production, and the other 60% rely on acquisitions.

Just like the Weichuang Medical just discussed, the process of continuously splitting subsidiaries and expanding new businesses is actually accompanied by a series of mergers and acquisitions.

This does not mean that everything is started from scratch.

And why is the rise of Qing Ning Group not like this? First, it made a large-scale acquisition of Hengrui Pharmaceutical, and then set its sights on the two major medical device giants, Vitron and Marui.

Just saying.

The mergers and acquisitions of Weichuang and Marui are all on a small scale. The acquisition targets are likely to be hundreds of millions, and the highest is a billions of mergers and acquisitions, while Qing Ning Group's mergers and acquisitions are often worth tens of billions.

The essence is the same.

"Then according to this, Marian should be very prosperous and it is an industry leader. Will it be willing to be acquired by us?" Zhang Shuo asked.

"Mai Rui is actually just a superficial beauty."

Since Lu Kai dared to propose the acquisition of Marui, he was naturally confident. He explained: "In fact, in the past one or two years, Marui's development has encountered a bottleneck and hit the ceiling of development."

"This can be seen from the fact that Marian's stock price has been flat since it was listed in the United States."

"Although China's medical device market has huge demand, the local medical device industry chain has problems such as duplication of low-end production capacity and waste of production resources. There is still an objective gap between the world's advanced levels."

“Both Vitron and Marui were initially engaged in the production of relatively low-end medical device products. Although they have made progress in the past few years, they are still stretched in the field of high-end medical devices.

This chapter is not over yet, please click on the next page to continue reading! "Especially some core components, such as CT equipment tubes, detectors, etc., almost all rely on imports and have no bargaining power, which in disguise increases the procurement cost.

.”

Such a situation is basically the same as that of the mobile phone and semiconductor industries.

It can also be regarded as the helplessness of latecomers!

"Because the development has reached a bottleneck and the stock price is flat, Marian's management has already considered delisting from the United States. One of the founders has even withdrawn from daily management of Marian and turned to the real estate industry."

The current real estate industry is still very popular.

"Unfortunately, the founder's real estate business is currently experiencing a crisis of tight capital chain. If we can offer a suitable price, we are sure to acquire the Marui shares from him."

Compared with Weichuang, Marui's shareholding structure is simpler.

In addition to 30% of the circulating shares on the market, the remaining 70% of the equity is basically held by the three founders, with the shareholdings being 32.2%, 31.3% and 6.5% respectively.

The founder who wants to engage in real estate has a shareholding ratio of 31.3%.

"On the basis of acquiring the equity from the founder, if we can help Marian complete the privatization and delisting from the US stock market, we can obtain the controlling stake of Marian."

"So that's it."

Zhang Shuo then suddenly realized and asked with a smile: "What is the current market value of Marui?"

"If you convert it, it's almost 18.5 billion. The total cost of acquiring the founder's shares, plus privatization and delisting, is about 12 billion."

Lu Kai has indeed done enough homework.

"Okay, let's do it together."

Zhang Shuo is also a powerful person. Acquiring one company is an acquisition, and acquiring two companies is also an acquisition.

"I have said before that if the group does not enter the pharmaceutical industry, it will be fine. Once it enters, it will inevitably make a name for itself. Take the field of medical devices as an example. The positioning of Qing Ning Group is not to dominate China.

Instead, we have to compete with global medical giants such as Medtronic, Johnson & Johnson, and Siemens Medical."

"The lowest, the lowest, no matter what, we have to be among the top ten global medical device giants."

This is decided.

Since the birth of Qing Ning Group, it has embarked on a path of great expansion and great cooperation.

Independent research and development is of course important, but whether it is the research and development of new drugs or new medical device products, it is a time-consuming task, and results cannot be seen in a short time.

The best way is through mergers and acquisitions, and mergers and acquisitions on a global scale.

Because there are a large number of small medical device companies in both the United States and Europe. These companies have been focusing on cutting-edge technologies in certain fields for decades.

Once good technologies and products are developed, they will be acquired by large companies.

In China, many small medical device companies are eagerly waiting to go on the market before they have mature commercial products.

After going public, due to pressure from investors, it stopped investing in innovation in order to ensure profits.

How sad?

This is one of the reasons why Zhang Shuo decided to let Moya go down personally.

At the current time point, Chinese companies are not very restrictive in their overseas mergers and acquisitions. If it is delayed for another three to five years, even if they spend a lot of money, they will probably be unable to do so.

Except for acquisitions.

In the future, robots will be widely used in the field of medical equipment, which is an excellent outlet for overtaking in corners, and Qing Ning Group cannot miss it.

As for the layout in the field of robots, WALLI Intelligent Manufacturing is a good platform.

And of course there is the Fertile Soil Research Institute.

Therefore, the fact that Sprout Group is involved in the pharmaceutical industry does not mean that there is really no way to empower Qing Ning Group. There are still some cross-cutting fields that can produce chemical reactions.

And it’s well worth looking forward to!

“Ting!

"

After listening to Zhang Shuo's speech, Sun Yang was both excited and stressed.

Needless to say, he was very excited. Sun Yang truly realized that Qing Ning Group would undoubtedly be a broader development platform with more potential than Hengrui Pharmaceutical's previous "small business".

It can even be said that it has risen to a big level.

Before coming to the Binhai City headquarters, Sun Yang originally thought that the group headquarters would be cautious about whether to acquire Weichuang. Who would have expected that it would even want to acquire the larger Maruis.

If these two acquisitions are completed, Qingning Group will definitely become the giant and leader in China's medical device field, and it will be the only one.

Even with the global medical device giant, you can compete with others.

Zhang Shuo's speech undoubtedly proved this point. Perhaps, from the birth of Qing Ning Group, it was destined to shoulder the mission of challenging the global pharmaceutical giants.

Just like what Maiya's Maili Group and Daosui Group have been doing.

How could Sun Yang not be excited?

But while he was excited, facing such an extremely arduous task, as the helmsman of Qing Ning Group, it is conceivable that Sun Yang was under great pressure.

You know, in a powerful system like the Germination Group, if you don't do well, you can only resign voluntarily.

There is no second way!

Even though Sun Yang is the founder and one of the major shareholders of Hengrui Pharmaceutical, he does not have any privileges.

The key is.

The parent company has already allocated so many resources. If it really fails, Sun Yang himself will have no shame in staying in this position anymore.

You have to give it a try!

When he thought of this, Sun Yang was still a little excited, vaguely remembering the feeling he had when he first started his business.

This is so rare!

And just half a month ago, Sun Yang was still hesitating and unsure whether he should agree to the Qing Ning Group's acquisition and whether he should join the Germination System.

At this moment, I was worried about gains and losses, for fear of being eliminated by Germination.

I'm afraid no one will believe me if I tell you.

It can be seen that within the Germination Group, including Zhang Shuo, the soul of Germination, there is indeed a magical power that can make countless high-level talents willing to fight for it.
Chapter completed!